Jennison Associates
RVMD icon

Jennison Associates’s Revolution Medicines RVMD Stock Holding History

Jennison Associates’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.6M Sell
280,933
-26,444
-9% -$3.86M 0.03% 230
2026
Q1 		$29.9M Buy
307,377
+2,117
+0.7% +$214K 0.02% 286
2025
Q4 		$24.3M Buy
+305,260
New +$20M 0.01% 310
2020
Q2 		– Sell
-200,490
Closed -$4.39M – 693
2020
Q1 		$4.39M Buy
+200,490
New +$5.55M 0.01% 409

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jennison Associates's RVMD Position: Q2 2026 in Review

Jennison Associates reduced its Revolution Medicines (RVMD) stake by 8.6% in Q2 2026, selling an estimated $3.86M and leaving 280,933 shares worth $52.6M. The position accounts for 0.03% of the portfolio, ranked #230.

Jennison Associates first reported a position in RVMD in Q1 2020 and has held it in 4 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Jennison Associates held 280,933 shares of Revolution Medicines worth $52.6M as of Q2 2026.
  • Jennison Associates sold 26,444 Revolution Medicines shares in Q2 2026, an estimated $3.86M.
  • Revolution Medicines made up 0.03% of Jennison Associates's portfolio in Q2 2026, its #230 holding.
  • Jennison Associates first reported a position in Revolution Medicines in Q1 2020 and has held it in 4 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.